<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04509336</url>
  </required_header>
  <id_info>
    <org_study_id>2020-87</org_study_id>
    <nct_id>NCT04509336</nct_id>
  </id_info>
  <brief_title>Orphenadrine Versus Baclofen in Treatment of Muscle Cramps in Cirrhotic Patients</brief_title>
  <official_title>Comparison of the Efficacy and Safety of Orphenadrine Versus Baclofen in Treatment of Muscle Cramps in Cirrhotic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Muscle cramps are commonly affects patients with cirrhosis. It adversely influences the&#xD;
      quality of life of cirrhotic patients. Treatment of muscle cramps still challenging owing to&#xD;
      the diversity of the responsible pathophysiological mechanisms.The effectiveness of baclofen&#xD;
      and orphenadrine in controlling muscle cramps in cirrhotic patients has been presented in&#xD;
      recent randomised controlled clinical trials;however, the comparative efficacy and safety&#xD;
      between these two therapeutic options has not been previously investigated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 20, 2020</start_date>
  <completion_date type="Anticipated">September 20, 2021</completion_date>
  <primary_completion_date type="Actual">December 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the difference in the number of muscle cramps between the orphenadrine and baclofen groups at the end of treatment</measure>
    <time_frame>12 weeks</time_frame>
    <description>Questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The difference in severity of cramps between orphenadrine and baclofen groups at the end of treatment</measure>
    <time_frame>12 weeks</time_frame>
    <description>Visual analogue scale (VAS)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>orphenadrine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>orphenadrine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baclofen group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Baclofen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Orphenadrine</intervention_name>
    <description>100 mg twice daily</description>
    <arm_group_label>orphenadrine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baclofen</intervention_name>
    <description>initial dose of 10 mg tablet once daily, dose will be gradually increased according to the patients responses</description>
    <arm_group_label>Baclofen group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-70 years&#xD;
&#xD;
          2. Cirrhotic patients complaining of frequent muscle cramps (&gt;3 per week) for at least a&#xD;
             month&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with allergy to study drugs&#xD;
&#xD;
          2. Renal impairment&#xD;
&#xD;
          3. Peripheral vascular disease&#xD;
&#xD;
          4. Peripheral neuropathy&#xD;
&#xD;
          5. Glaucoma&#xD;
&#xD;
          6. Prostatic enlargement&#xD;
&#xD;
          7. Pregnancy and lactation&#xD;
&#xD;
          8. Patients taking calcium channel blockers, and conjugated estrogens&#xD;
&#xD;
          9. Patients taking vitamin E, taurine, carnitine, narcotic pain medications, muscle&#xD;
             relaxants, nonsteroidal anti-inflammatory drugs, or antispastic agents during and for&#xD;
             2 weeks following the study&#xD;
&#xD;
         10. Patients with alcoholic cirrhosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Assem Elfert</last_name>
    <role>Study Chair</role>
    <affiliation>Faculty of Medicine, Tanta University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sherif Abd-Elsalam</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine, Tanta University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tanta University Hospitals</name>
      <address>
        <city>Tanta</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>July 21, 2020</study_first_submitted>
  <study_first_submitted_qc>August 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2020</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Noha Mansour</investigator_full_name>
    <investigator_title>Lecturer of clinical pharmacy, pharmacy practice department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscle Cramp</mesh_term>
    <mesh_term>Spasm</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Orphenadrine</mesh_term>
    <mesh_term>Baclofen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

